AbbVie (ABBV) was granted FDA orphan designation for an antibody drug conjugate comprising monoclonal antibody anti-SEZ6 IgG1 antibody conjugated to a Top1 inhibitor as a treatment of small cell lung cancer, according to a post to the FDA website.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV: